NCT03907852 2025-08-27
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
TCR2 Therapeutics
TCR2 Therapeutics
National Institutes of Health Clinical Center (CC)